Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
JPS6022694B2 - Novel 2-(2-fluoro-4-biphenyl)propionic acid ester derivative - Google Patents
[go: Go Back, main page]

JPS6022694B2 - Novel 2-(2-fluoro-4-biphenyl)propionic acid ester derivative - Google Patents

Novel 2-(2-fluoro-4-biphenyl)propionic acid ester derivative

Info

Publication number
JPS6022694B2
JPS6022694B2 JP7570677A JP7570677A JPS6022694B2 JP S6022694 B2 JPS6022694 B2 JP S6022694B2 JP 7570677 A JP7570677 A JP 7570677A JP 7570677 A JP7570677 A JP 7570677A JP S6022694 B2 JPS6022694 B2 JP S6022694B2
Authority
JP
Japan
Prior art keywords
fluoro
biphenyl
propionic acid
compound
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP7570677A
Other languages
Japanese (ja)
Other versions
JPS5412356A (en
Inventor
寛治 野田
晃 中川
敏治 本村
和喜 野口
博之 井出
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hisamitsu Pharmaceutical Co Inc
Original Assignee
Hisamitsu Pharmaceutical Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hisamitsu Pharmaceutical Co Inc filed Critical Hisamitsu Pharmaceutical Co Inc
Priority to JP7570677A priority Critical patent/JPS6022694B2/en
Publication of JPS5412356A publication Critical patent/JPS5412356A/en
Publication of JPS6022694B2 publication Critical patent/JPS6022694B2/en
Expired legal-status Critical Current

Links

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

【発明の詳細な説明】 本発明は一般式(1) (式中、nは1または2の整数を、RIは水素原子また
は低級アルキル基を、R2は‘ィ}水酸基、【o’トリ
ハロメチル基、し一ピリジル基、Bフェニル基または■
ハロゲン原子、低級アルキル基またはトリフルオロメチ
ル基で置換されたフェニル基を意味する)で表わされる
新規な2一(2−フルオロ−4ービフェニル)プロピオ
ン酸ェステル誘導体に関するものである。
Detailed Description of the Invention The present invention is based on the general formula (1) (where n is an integer of 1 or 2, RI is a hydrogen atom or a lower alkyl group, R2 is a hydroxyl group, [o' trihalomethyl group, pyridyl group, B phenyl group, or ■
The present invention relates to a novel 2-(2-fluoro-4-biphenyl)propionic acid ester derivative represented by a phenyl group substituted with a halogen atom, a lower alkyl group, or a trifluoromethyl group.

本発明の化合物は文献未載の新規化合物であり、顕著な
鎮痛作用及び抗炎症作用を有し医薬品として産業上有用
な化合物である。
The compound of the present invention is a novel compound that has not been described in any literature, and has significant analgesic and anti-inflammatory effects and is industrially useful as a pharmaceutical.

前記一般式(1)におけるRI及びR2に就いて更に具
体的に説明すると、RIは水素原子又はメチル、エチル
等の低級アルキル基を、R2は水酸基、トリクロロメチ
ル基及びトリフルオロメチル基等のトリハロメチル基を
、ピリジル基は2ーピリジル基、3ーピリジル基及び4
ーピリジル基を、フェニル基、または塩素、臭素、沃素
、弗素等のハロゲン原子、メチル、エチル、プロピル、
イソプロピル、nープチル、イソプチル、tertーブ
チル等の低級アルキル基またはトリフルオロメチル基等
で任意の位置に1〜2個置換したフェニル基を表わす。
To explain RI and R2 in the general formula (1) more specifically, RI represents a hydrogen atom or a lower alkyl group such as methyl or ethyl, and R2 represents a trihalogen group such as a hydroxyl group, a trichloromethyl group, or a trifluoromethyl group. Methyl group, pyridyl group is 2-pyridyl group, 3-pyridyl group and 4-pyridyl group.
- Pyridyl group, phenyl group, halogen atom such as chlorine, bromine, iodine, fluorine, methyl, ethyl, propyl,
It represents a phenyl group substituted with 1 or 2 lower alkyl groups such as isopropyl, n-butyl, isobutyl, tert-butyl, or trifluoromethyl group at any position.

従来、一般式(1)で表わされる化合物と類似構造を有
する化合物として一般式(la)で表わされる2一(2
ーフルオロー4ービフェニル)プロピオン酸が公知であ
る。
Conventionally, 2-(2
-fluoro-4-biphenyl)propionic acid is known.

この化合物はすぐれた鎮痛作用及び抗炎症作用等の薬理
活性を示す反面、胃腸障害等の副作用があり使用上慎重
に投与されなければならないという欠点を有している。
そこで本発明者等は係る副作用を転減し且つ強力な鎮痛
作用及び抗炎症作用を有する新規化合物を求め鋭意研究
を重ねた結果、一般式(la)で表わされる化合物をェ
ステル誘導体(1)に変換したところ胃腸障害が著しく
軽減され且つ鎮痛作用、抗炎症作用も前記化合物(la
)と同程度又はそれ以上の薬理作用を有することを見出
し、更には非ステロイド系外用消炎剤の開発を目的とし
て局所に適用したところ顕著な抗炎症作用を有し、且つ
経皮吸収が非常にすぐれていることを見出し、本発明を
完成したのである。以下に本発明にかかわる化合物の代
表的なものを列挙する。
Although this compound exhibits excellent pharmacological activities such as analgesic and anti-inflammatory effects, it has the disadvantage that it has side effects such as gastrointestinal disorders and must be administered with caution.
Therefore, the present inventors conducted intensive research in search of a new compound that reduces such side effects and has strong analgesic and anti-inflammatory effects, and as a result, the compound represented by the general formula (la) was converted into an ester derivative (1). When converted, gastrointestinal disorders were significantly alleviated, and the compound (la
), and when applied topically for the purpose of developing a non-steroidal topical anti-inflammatory agent, it was found to have a remarkable anti-inflammatory effect and was highly absorbable through the skin. They discovered that the method was superior and completed the present invention. Representative compounds related to the present invention are listed below.

2−(2ーフルオo−4ービフエニル)ブロピオン酸−
o−フルオロベンジルェステル2一(2ーフルオロ−4
ービフエニル)ブロピオン酸−mーフルオロベンジルェ
ステル2−(2−フルオロー4−ビフヱニル)プロピオ
ン酸−p−フルオロベンジルェステル2一(2ーフルオ
o−4ービフエニル)プロピオン酸−oークロロベンジ
ルェステル2一(2−フルオロ−4−ビフエニル)プロ
ピオン酸−m−クロロベンジルェステル2−(2ーフル
オロー4ービフエニル)プロピオン酸−p−クロロベン
ジルェステル2一(2ーフルオロ−4−ビフエニル)ブ
ロピオン酸−o−メチルベンジルェステル2一(2−フ
ルオロー4ービフエニル)プロピオン酸−mーメチルベ
ンジルェステル2一(2ーフルオロ−4−ビフエニル)
プロビオン酸−p−メチルベンジルェステル2一(2−
フルオロ−4ービフエニル)プロピオン酸−o−トリフ
ルオロメチルベンジルェステノレ2一(2−フルオロー
4ービフエニル)プロピオン酸−mートリフルオロメチ
ルベンジルェステノレ2−(2ーフルオo−4−ビフエ
ニル)プロピオン酸−p−トリフルオロメチルベンジル
ェステ′レ2一(2ーフルオロー4ービフエニル)プ。
2-(2-fluoro-4-biphenyl)propionic acid-
o-Fluorobenzyl ester 2-(2-fluoro-4
-biphenyl)propionic acid-m-fluorobenzyl ester 2-(2-fluoro-4-biphenyl)propionic acid-p-fluorobenzyl ester 2-(2-fluoro-4-biphenyl)propionic acid-o-chlorobenzyl ester 2 1-(2-fluoro-4-biphenyl)propionic acid-m-chlorobenzyl ester 2-(2-fluoro-4-biphenyl)propionic acid-p-chlorobenzyl ester 2-(2-fluoro-4-biphenyl)propionic acid-o -Methylbenzyester 2-(2-fluoro-4-biphenyl)propionic acid-m-Methylbenzyester 2-(2-fluoro-4-biphenyl)
Probionic acid-p-methylbenzyl ester 2-(2-
fluoro-4-biphenyl)propionic acid-o-trifluoromethylbenzylesterol2-(2-fluoro-4-biphenyl)propionic acid-m-trifluoromethylbenzylesterol2-(2-fluoro-4-biphenyl)propionic acid- p-Trifluoromethylbenzylester 2-(2-fluoro-4-biphenyl)p.

ピオン酸−2ーピリジルメチルェステル2一(2−フル
オロー4ービフエニル)プロピオン酸−3−ピリジルメ
チルェステル2一(2−フルオロ−4−ビフエニル)プ
ロピオン酸−4ーピリジルメチルェステル2一(2ーフ
ルオロー4−ピフエニル)プロピオン酸−Q−メチルベ
ンジルェステル2−(2−フルオロー4−ビフエニル)
プロピオン酸−Q−エチルベンジルェステル2−(2−
フルオロ−4−ビフエニル)プロピオン酸−Qーメチル
−o−メチルベンジルェステ′レ2一(2−フルオロ−
4−ビフエニル)プロピオン酸−Qーメチル−m−メチ
ルベンジルェステ′レ2一(2−フルオo−4ーピフエ
ニル)プロピオン酸−Qーメチルーpーメチルベンジル
ェステノレ2一(2ーフルオロー4ービフエニル)プロ
ピオン酸−Qーメチル−o一クロロベンジルェステ′レ
2一(2−フルオロ−4−ビフエニル)プロピオン酸−
Qーメチル−mークロロベンジルェステノレ2一(2ー
フルオロ−4−ビフエニル)プロピオン酸−Q−メチル
−p−クロロベンジルェステ′レ2一(2−フルオロー
4ービフエニル)プロピオン酸−Q−メチル−o−フル
オロベンジルェステノレ2−(2ーフルオロ−4ービフ
エニル)プロピオン酸−Qーメチル−m−フルオロベン
ジルェステル2−(2−フルオロ−4−ピフエニル)プ
ロピオン酸−Q−メチル−pーフルオロベンジルヱステ
/し2一(2ーフルオロー4ービフエニル)プロピオン
酸−Qーメチルーo−トリフルオロメチルベンジルエス
テル2一(2−フルオロー4−ビフエニル)プロピオン
酸−Q−メチル一mートリフルオロメチルベンジルエス
テル2−(2−フルオロー4ービフエニル)プロピオン
酸−Qーメチル−pートリフルオロメチルベンジルヱス
テル2一(2−フルオロ−4ービフヱニル)プロピオン
酸ーフェネチルヱステル2一(2−フルオロー4−ビフ
エニル)プロピオン酸−pーフルオロフェネチルェステ
ル2一(2−フルオロー4−ビフエニル)プロピオン酸
−ペンジルェステル2一(2ーフルオロー4ービフエニ
ル)プロピオン酸−2・2・Zートリフルオロェチルェ
ステ′レ2一(2ーフルオロ−4ービフエニル)プロピ
オン酸−2ーハィドロキシヱチルェステル以下に本発明
に係る化合物の製造方法に就いて述べる。
2-pyridylmethyl propionate 2-(2-fluoro-4-biphenyl) 3-pyridylmethyl propionate 2-(2-fluoro-4-biphenyl) 4-pyridyl methyl propionate 2-(2-fluoro-4-biphenyl) 2-(2-fluoro-4-biphenyl)propionic acid-Q-methylbenzyl ester 2-(2-fluoro-4-biphenyl)
Propionic acid-Q-ethylbenzyl ester 2-(2-
fluoro-4-biphenyl)propionate-Q-methyl-o-methylbenzylester 2-(2-fluoro-
4-biphenyl)propionic acid-Q-methyl-m-methylbenzylester-2-(2-fluoro-4-piphenyl)propionic acid-Q-methyl-p-methylbenzylester-2-(2-fluoro-4-biphenyl)propionic acid- Q-Methyl-o-chlorobenzylester-2-(2-fluoro-4-biphenyl)propionic acid-
Q-Methyl-m-chlorobenzylesterol2-(2-fluoro-4-biphenyl)propionic acid-Q-methyl-p-chlorobenzylesterol2-(2-fluoro-4-biphenyl)propionic acid-Q-methyl-o -Fluorobenzylester 2-(2-fluoro-4-biphenyl)propionic acid-Q-methyl-m-fluorobenzylester 2-(2-fluoro-4-piphenyl)propionic acid-Q-methyl-p-fluorobenzylester /2-(2-fluoro-4-biphenyl)propionic acid-Q-methyl-o-trifluoromethylbenzyl ester2-(2-fluoro-4-biphenyl)propionic acid-Q-methyl-m-trifluoromethylbenzyl ester 2-(2 -Fluoro-4-biphenyl)propionic acid-Q-Methyl-p-trifluoromethylbenzylester 2-(2-fluoro-4-biphenyl)propionic acid-phenethylester 2-(2-fluoro-4-biphenyl)propionic acid-p- Fluorophenethyl ester 2-(2-fluoro-4-biphenyl)propionic acid-penzyl ester 2-(2-fluoro-4-biphenyl)propionic acid-2,2-Z-trifluoroethyl ester 2-(2-fluoro-4-biphenyl) Propionic acid-2-hydroxyethyl ester A method for producing the compound according to the present invention will be described below.

本発明の化合物は下記に記載する方法によって収率よく
得ることが出来るがこれは一例にすぎず、当然他の化学
的類似方法によっても製造される。製造法A 但し、n、RI及びR2は前記と同じ意味を有する。
The compound of the present invention can be obtained in good yield by the method described below, but this is only an example, and of course it can also be produced by other chemically similar methods. Manufacturing method A However, n, RI and R2 have the same meanings as above.

製造法B 但し、Xはハロゲン原子又は有機スルホニル基を、Mは
アルカリ金属を、n、RI及びR2は前記と同じ意味を
有する。
Manufacturing method B However, X is a halogen atom or an organic sulfonyl group, M is an alkali metal, and n, RI and R2 have the same meanings as above.

製造法C 但し、n、RI及びR2は前記と同じ意味を有する。Manufacturing method C However, n, RI and R2 have the same meanings as above.

製造法D 但し、n、RI及びR2は前記と同じ意味を有る。Manufacturing method D However, n, RI and R2 have the same meanings as above.

製造法E 但し、n、RI及びR2は前記と同じ意味を有する。Manufacturing method E However, n, RI and R2 have the same meanings as above.

製造法F 但し、n、RI及びR2は前記と同じ意味を有する。Manufacturing method F However, n, RI and R2 have the same meanings as above.

製造法G 但し、n、RI及びR2は前記と同じ意味を有する。Manufacturing method G However, n, RI and R2 have the same meanings as above.

製造法日 但し、Rは低級アルキル基をn、RI及びR2は前記と
同じ意味を有する。
Manufacturing method: However, R represents a lower alkyl group, and RI and R2 have the same meanings as above.

製造法I 但し、n、RI及びR2は前記と同じ意味を有する。Manufacturing method I However, n, RI and R2 have the same meanings as above.

次に本発明の実施方法を具体的に説明する。Next, a method for implementing the present invention will be specifically explained.

製造方法Aは化合物(la)と一般式(D)で表わされ
る化合物を硫酸、ポリリン酸、pートルェンスルホン酸
等の脱水剤の存在下、一般式(ロ)で表わされるアルコ
ール類を溶媒を兼ねて過剰に使用するか又はベンゼン、
トルェン、キシレン等の有機溶媒を使用し還流下に反応
させればよい。製造方法Bは化合物(la)をアルカリ
金属で処理して(lb)となし、次に一般式(m)で表
わされる化合物をベンゼン、トルェン、キシレン、テト
ラヒドロフラン、ジオキサン、ジグリム、ジメチルホル
ムアミド、ジメチルスルホキシドの有機溶媒中、室温は
必要に応じ加熱下に反応させれば反応は速やかに進行す
る。
Production method A involves compound (la) and a compound represented by general formula (D) in the presence of a dehydrating agent such as sulfuric acid, polyphosphoric acid, p-toluenesulfonic acid, etc., and an alcohol represented by general formula (b) as a solvent. or benzene,
The reaction may be carried out under reflux using an organic solvent such as toluene or xylene. Production method B involves treating compound (la) with an alkali metal to form (lb), and then converting the compound represented by general formula (m) into benzene, toluene, xylene, tetrahydrofuran, dioxane, diglyme, dimethylformamide, dimethylsulfoxide. The reaction proceeds quickly in an organic solvent at room temperature or with heating if necessary.

製造法C及びDは一般式(lc)及び(ld)で表わさ
れる化合物をパラジウム−炭素、酸化白金等の触媒の存
在下に接触還元することによって目的化合物(1)を得
ることが出釆る。
In production methods C and D, the target compound (1) can be obtained by catalytic reduction of the compounds represented by the general formulas (lc) and (ld) in the presence of a catalyst such as palladium-carbon or platinum oxide. .

製造方法Eは化合物(le)のアミ/基を弗秦化剤の存
在下にジアゾ化してフルオロジアゾニウム誘導体を作り
、次に加熱分解して相当するフルオロ化合物とするシー
マン反応を利用することによって製造される。
Production method E is produced by diazotizing the amine/group of compound (le) in the presence of a fluorinating agent to produce a fluorodiazonium derivative, and then thermally decomposing it to produce the corresponding fluoro compound using the Schiemann reaction. be done.

製造方法Fは化合物(la)をハロゲン化剤で処理して
酸ハライド(lf)とし、次に(ロ)で表わされるアル
コール類を反応に関与しない有機溶媒(例えば、テトラ
ヒドロフラン、ジグリム、ジオキサン、アセトン、クロ
ロホルムベンゼン、トルェン等)中、ピリジン、トリメ
チルアミン、トリェチルァミン、トリェチルアミン、炭
酸カリウム、炭酸ナトリウム等の脱酸剤の存在下に反応
させればよい。
In production method F, compound (la) is treated with a halogenating agent to form an acid halide (lf), and then the alcohol represented by (b) is treated with an organic solvent that does not participate in the reaction (e.g., tetrahydrofuran, diglyme, dioxane, acetone). , chloroformbenzene, toluene, etc.) in the presence of a deoxidizing agent such as pyridine, trimethylamine, triethylamine, triethylamine, potassium carbonate, and sodium carbonate.

製造方法Gは化合物(1g)と一般式(ロ)で表わされ
るアルコール類を鱗酸(硫酸、塩酸等)の存在下、使用
するアルコール類(0)を溶媒を兼ねて反応させるか又
はベンゼン、トルヱン等の反応に関与しない有機溶媒中
還流下反応させればよい。
Production method G involves reacting the compound (1g) with an alcohol represented by the general formula (b) in the presence of scale acid (sulfuric acid, hydrochloric acid, etc.) with the alcohol (0) used also serving as a solvent, or using benzene, The reaction may be carried out under reflux in an organic solvent that does not participate in the reaction, such as toluene.

製造方法日は化合物(lh)に対して一般式(0)で表
わされるアルコール類を過剰モル使用し直接又は少量の
アルカリ金属の存在下、使用するアルコール類又は有機
溶媒(例えば、ベンゼン、トルヱン、キシレン等)の沸
点か又は沸点付近で加熱下、反応させればェステル交換
反応が進行する。
The production method uses an excess molar amount of the alcohol represented by the general formula (0) relative to the compound (lh), and the alcohol or organic solvent used (for example, benzene, toluene, If the reaction is carried out under heating at or near the boiling point of xylene, etc., the transesterification reaction will proceed.

製造方法1は化合物(li)と一般式(0)で表わされ
るアルコール類とを酸触媒の存在下又は直接加熱するか
、反応に関与しない有機溶媒中で過剰のアルコール類(
0)と加熱下に反応させればよい。
Production method 1 involves heating the compound (li) and the alcohol represented by the general formula (0) in the presence of an acid catalyst or directly, or heating the compound (li) and the alcohol represented by the general formula (0) in an organic solvent that does not participate in the reaction in an excess amount of the alcohol (
0) under heating.

次に、本発明の化合物に関する薬理実験結果を示す。Next, the results of pharmacological experiments regarding the compounds of the present invention will be shown.

実験例 1 ラットでのカラゲニン足浮腫抑制作用に対する実験(実
験方法):体重140〜150夕のwistar系雄性
ラツトを1群5匹として、1報時間絶食後、試験化合物
の経口投与を行ない1時間後に、ラットの足鍵に1%カ
ラゲニン水溶液0.1M円注射した。
Experimental Example 1 Experiment on the inhibitory effect of carrageenan on paw edema in rats (experimental method): A group of 5 male Wistar rats weighing 140-150 kg were fasted for 1 hour, and then the test compound was orally administered for 1 hour. Afterwards, a 0.1 M circle of 1% carrageenan aqueous solution was injected into the rat's foot pad.

起炎剤注射3時間後に足容積を測定し、下記の式より足
浮腫率および浮腫抑制率を求めた。なお、試験化合物は
0.5%トラガントゴム水溶液に懸濁し、対照群には溶
媒のみを投与した。浮腫率(%)=カラゲニン注射後足
容積−カラゲニン注射前足容積X,。
The paw volume was measured 3 hours after the injection of the inflammatory agent, and the paw edema rate and edema suppression rate were calculated from the following formula. The test compound was suspended in a 0.5% aqueous solution of gum tragacanth, and only the solvent was administered to the control group. Edema rate (%) = carrageenin injection hind paw volume - carrageenin injection paw volume X.

〇カラゲニン注射前足容積浮腫抑制率(%)=対照群の
浮腫率 薬物処置群の.浮腫率XI。
〇Carrageenin injection paw volume edema suppression rate (%) = edema rate of control group, drug-treated group. Edema rate XI.

〇対照群の浮腫率結果を表1に示す。〇The edema rate results for the control group are shown in Table 1.

表1 ラシトでのヵラゲニン足浮腫抑制作用比較化合物
:2一(2−フルオロー4ービフェニル)プロピオン酸
メチルェステル**:危険率1%、*;危険率5%で対
照群と比較して、浮腫率にて有意差があることを示す。
Table 1 Comparative effect of carrageenin on paw edema inhibition in Lacito This shows that there is a significant difference.

実験例 2ラットでの胃潰擬惹起作用に対する実険 (実験方法):体重170〜180夕のwistar系
雄性ラットを1群7匹として、2独時間絶食後、試験化
合物の経口投与を行ない3.虫篭間後にラットを放皿致
死させ、胃を摘出した。
Experimental Example 2 Actual risk of gastric ulcer-inducing effect in rats (experimental method): Groups of 7 male Wistar rats weighing 170-180 kg were given oral administration of the test compound after fasting for 2 hours. .. After incubation, the rats were sacrificed in a plate and their stomachs were removed.

1%ホルマリン液10泌を胃内に注入、固定後、胃を切
開し、ェロジオンの有無を観察した。
After 10 minutes of 1% formalin solution was injected into the stomach and fixed, the stomach was incised and the presence or absence of erodion was observed.

なお、試験化合物は0.5%トラガントゴム水溶液に懸
濁し、対照群には溶媒のみを投与した。実験結果を表2
に示す。
The test compound was suspended in a 0.5% aqueous solution of gum tragacanth, and only the solvent was administered to the control group. Table 2 shows the experimental results.
Shown below.

表2 ラットでの胃潰傷惹起作用 ※比較化合物は実験例1で使用したものと同一化合物で
ある。
Table 2 Gastric ulcer-inducing effect in rats *The comparative compound is the same compound used in Experimental Example 1.

以上の実験例1および2の実験結果より明らかな如く、
本願発明の化合物は顕著な抗炎症作用を有し、しかも、
胃に対する濃蕩形成も著しく減少することが判明した。
As is clear from the experimental results of Experimental Examples 1 and 2 above,
The compound of the present invention has a remarkable anti-inflammatory effect, and furthermore,
It was also found that the formation of gastrointestinal tracts in the stomach was significantly reduced.

以下に実施例を示し本発明を更に具体的に説明する。実
施例 1 2一(2ーフルオロ−4−ビフエニル)プロピオン酸2
.44夕、2′・2・2ートリフルオロェチルアルコー
ル8の‘と濃硫酸3泌の混合物を油裕上90〜100o
oで6時間加熱した。
EXAMPLES The present invention will be explained in more detail with reference to Examples below. Example 1 2-(2-fluoro-4-biphenyl)propionic acid 2
.. On the evening of April 44, a mixture of 8 parts of 2', 2, 2-trifluoroethyl alcohol and 3 parts of concentrated sulfuric acid was heated to 90 to 100 o'clock on an oil bath.
The mixture was heated at o for 6 hours.

反応終了後、反応物を氷水に注ぎエーテルで注出後、エ
ーテル層を5%炭酸ナトリウム溶液及び水で十分洗った
後脱水した。エーテルを留去して得られた油状物をシリ
カゲルを充填したカラムに吸着させジクロルメタンにて
展開した。第一流出部の溶媒を減圧下に蟹去し、淡黄色
油状の2−(2−フルオロ−4−ビフェニル)ブロピオ
ン酸−2′・2・2−トリフルオロェチルヱステル2.
3夕を得た。この物質のIRスペクトル及びMSスペク
トルは次の通りであった。
After the reaction was completed, the reaction product was poured into ice water, poured out with ether, and the ether layer was thoroughly washed with a 5% sodium carbonate solution and water, and then dehydrated. The oil obtained by distilling off the ether was adsorbed onto a column packed with silica gel and developed with dichloromethane. The solvent in the first outflow portion was removed under reduced pressure, and 2-(2-fluoro-4-biphenyl)propionic acid-2',2,2-trifluoroethyl ester was obtained as a pale yellow oil.
I got 3 nights. The IR spectrum and MS spectrum of this material were as follows.

IRスペクトル:レc=0 175比汎‐IMSスペ
クトル:M十 326実施例 2 2−(2ーフルオロー4ービフエニル)ブロピオン酸ナ
トリウム2.66夕をジメチルホルムアミド20の‘に
溶解させ、p−フルオロベンジルクロラィド2.16夕
を加え、80〜9び○で3時間反応させた。
IR spectrum: Rec = 0 175 Specific spectrum - IMS spectrum: M 326 Example 2 2.66% of sodium 2-(2-fluoro-4-biphenyl)propionate was dissolved in 20% of dimethylformamide, and p-fluorobenzylchloride was dissolved in 20% of dimethylformamide. Added 2.16 hours of hydroxide and allowed to react at 80 to 9 degrees for 3 hours.

反応終了後、減圧下に溶媒を蟹去し務溝に水を加えエー
テルで抽出、脱水後、エーテルを蟹去し残澄をシリカゲ
ルを充填したカラムに吸着させクロロホルムにて展開し
た。第一流出部の溶媒を減圧下に蟹去し、淡黄色油状の
2一(2−フルオロ−4ービフェニル)プロピオン酸−
p−フルオロベンジルェステル2.50夕を得た。この
物資のRスペクトル及びMSスペクトルは次の通りであ
った。
After the reaction was completed, the solvent was removed under reduced pressure, water was added to the solution, and the mixture was extracted with ether. After dehydration, the ether was removed and the residue was adsorbed onto a column packed with silica gel and developed with chloroform. The solvent in the first outflow portion was removed under reduced pressure, and 2-(2-fluoro-4-biphenyl)propionic acid was obtained as a pale yellow oil.
2.50 g of p-fluorobenzyl ester were obtained. The R spectrum and MS spectrum of this material were as follows.

mスペクトル:レCニ0 173比ネ‐IM憶スペク
トル:M+ 352実施例 3 2−(2ーフルオロー4−ビフヱニル)アクリル酸−o
ーメチルベンジルェステル1.73夕、酸化白金0.0
3夕及びエタノール20の上を用いて、常圧接触還元装
置を使用し、室温で水素添加した。
m spectrum: ReCni0 173 ratio N-IM memory spectrum: M+ 352 Example 3 2-(2-fluoro-4-bifenyl)acrylic acid-o
- Methyl benzyl ester 1.73 m, platinum oxide 0.0
Hydrogenation was carried out at room temperature using an atmospheric pressure catalytic reduction apparatus over 3 hours and 20 hours of ethanol.

反応終了後、触媒を除去し炉液を減圧下に留去し得られ
た残澄をシリカゲルを充填したカラムに吸着させクロロ
ホルムにて展開した。第一流出部の溶媒を減圧下に蟹去
し、淡黄色油状の2一(2−フルオロ−4ービフェニル
)プロピオン酸一o−メチルベンジルェステル1.62
夕を得た。この物質のIRスペクトル及びMSスペクト
ルは次の通りであった。
After the reaction was completed, the catalyst was removed and the reactor liquid was distilled off under reduced pressure. The resulting residue was adsorbed onto a column packed with silica gel and developed with chloroform. The solvent in the first outflow portion was removed under reduced pressure, and 1.62% of mono(2-fluoro-4-biphenyl)propionic acid mono-methylbenzyl ester was obtained as a pale yellow oil.
I got the evening. The IR spectrum and MS spectrum of this material were as follows.

IRスペクトル:レc=0 173比ネ‐IMSスペ
クトル:M十 乳8実施例 4 2ージメチルアミノー2−(2−フルオロ−4−ビフェ
ニル)プロピオン酸−m−トリフルオロメチルベンジル
エステル1.48夕、10%パラジウム一炭素0.25
夕及びエタノール40の【の混合物をオートクレープを
使用し80『Cで水素添加した。
IR spectrum: c=0 173 ratio N-IMS spectrum: M 8 Example 4 2-dimethylamino-2-(2-fluoro-4-biphenyl)propionic acid-m-trifluoromethylbenzyl ester 1.48 Evening, 10% palladium-carbon 0.25
A mixture of alcohol and 40% ethanol was hydrogenated at 80°C using an autoclave.

反応終了後、反応溶液を炉過し、炉液を減圧下に留去後
、得られた残澄をシリカゲルを充填したカラムに吸着さ
せクロロホルムにて展開した。第一流出部の溶媒を減圧
下に蟹去し、淡黄色油状の2−(2ーフルオロ−4−ビ
フェニル)プロピオン酸−mートリフルオロメチルベン
ジルエステル0.96夕を得た。この物質のIRスペク
トル及びMSスペクトルは次の通りであった。
After the reaction was completed, the reaction solution was filtered through a furnace, and the furnace liquid was distilled off under reduced pressure, and the resulting residue was adsorbed on a column filled with silica gel and developed with chloroform. The solvent in the first outflow portion was removed under reduced pressure to obtain 0.96 g of 2-(2-fluoro-4-biphenyl)propionic acid-m-trifluoromethylbenzyl ester as a pale yellow oil. The IR spectrum and MS spectrum of this material were as follows.

mスペクトル:レC=0 173&ス‐IMSスペクト
ル:M+ 402実施例 5 2一(2ーフルオロ−4−ビフユニル)プロピオン酸2
.44夕、塩化チオニル2.紙夕とベンゼン20の‘の
混合物を還流下、3時間反応させた。
m spectrum: RES C=0 173&S-IMS spectrum: M+ 402 Example 5 2-(2-Fluoro-4-bifuunyl)propionic acid 2
.. 44 evening, thionyl chloride 2. A mixture of 20% of paper and benzene was reacted under reflux for 3 hours.

次に減圧下に溶媒及び過剰の塩化チオニルを留出し、縛
られた残澄にテトラヒドロフラン20の‘と3ーピリジ
ンメタノール1.64夕を加えた後、水袷下にトリェチ
ルアミン1.50夕を加え室温で2時間燈拝した。反応
終了後、減圧下に溶媒を蟹出し残澄に水を加えエーテル
で抽出した。エーテル層を5%炭酸ナトリウム溶液及び
水で順次洗ったのち、脱水、減圧蟹去し偽られた残溝を
シリカゲルを充填したカラムに吸着させエーテルで展開
し溶出部の溶媒を留去して、淡黄色油状の2一(2−フ
ルオロー4−ビフェニル)プロピオン酸−3−ピリジル
メチルェステル2.05夕を得た。この物質のIRスペ
クトル及びMSスペクトルは次の通りであった。
Next, the solvent and excess thionyl chloride were distilled off under reduced pressure, and 20 parts of tetrahydrofuran and 1.64 parts of 3-pyridine methanol were added to the bound residue, and then 1.50 parts of triethylamine was added to the water. I lit it for 2 hours at room temperature. After the reaction was completed, the solvent was removed under reduced pressure, water was added to the residue, and the mixture was extracted with ether. The ether layer was sequentially washed with a 5% sodium carbonate solution and water, then dehydrated and removed under reduced pressure.The remaining residue was adsorbed onto a column packed with silica gel, developed with ether, and the solvent in the eluted portion was distilled off. 2.05 g of 2-(2-fluoro-4-biphenyl)propionic acid-3-pyridylmethyl ester was obtained as a pale yellow oil. The IR spectrum and MS spectrum of this material were as follows.

IRスペクトル:レcニ0 173比ス‐IMSスペ
クトル:M+ 斑5実施例 6 2−(2ーフルオロー4ービフエニル)プロピオン酸2
.44夕、塩化チオニル2.総夕とベンゼン20の‘の
混合物を還流下3時間反応させた。
IR spectrum: Rec 0 173 ratio - IMS spectrum: M+ mottling 5 Example 6 2-(2-fluoro-4-biphenyl)propionic acid 2
.. 44 evening, thionyl chloride 2. A mixture of 20% of soybean and benzene was reacted under reflux for 3 hours.

次に減圧下に溶媒及び過剰の塩化チオニルを磯出し、得
られた残経にベンゼン20の‘とQーメチルベンジルア
ルコール1.83夕を加えた後、氷冷下にトリェチルア
ミン1.50夕を加え室温で1時間渡洋しざらに遼流下
に1時間反応させた。反応終了後、減圧下に溶媒を留去
し、残簿に水を加えエーテルで抽出した。エーテル層を
5%炭酸ナトリウム溶液及び順次洗ったのち、脱水、減
圧留去し得られた銭澄をシリカゲルを充填したカラムに
吸着させエーテルで展開し、溶出部の溶媒を蟹去してプ
リズム晶の2−(2ーフルオロー4ービフエニル)プロ
ピオン酸−Qーメチルベンジルェステル2.3夕を得た
。この物質の融点及び元素分析値は次の通りであつた。
Next, the solvent and excess thionyl chloride were removed under reduced pressure, and to the resulting residue were added 20 parts of benzene and 1.83 parts of Q-methylbenzyl alcohol, and then 1.50 parts of triethylamine was added under ice-cooling. The reaction mixture was then allowed to react for 1 hour at room temperature under the current of the Liao stream. After the reaction was completed, the solvent was distilled off under reduced pressure, water was added to the residue, and the mixture was extracted with ether. The ether layer was sequentially washed with 5% sodium carbonate solution, dehydrated, and evaporated under reduced pressure. The resulting liquid was adsorbed onto a column packed with silica gel, developed with ether, and the solvent in the eluate was removed to form prism crystals. 2.3 ml of 2-(2-fluoro-4-biphenyl)propionic acid-Q-methylbenzyl ester was obtained. The melting point and elemental analysis values of this substance were as follows.

融点 90〜920 元素分析値 C23日2,F02 理論値 C:79.29H:6.雌 実測値 C:79.36H:602 実施例 7 2−(2ーフルオロー4−ビフエニル)プロピオン酸ナ
トリウム2.66夕をジメチルホルムアミド20の‘に
溶解しエチレンブロムヒドリン2.巡夕を加え60〜7
ぴ0にて1時間反応させた。
Melting point 90-920 Elemental analysis value C23 days 2, F02 theoretical value C:79.29H:6. Measured value C: 79.36H: 602 Example 7 2.66 g of sodium 2-(2-fluoro-4-biphenyl)propionate was dissolved in 20 g of dimethylformamide and 2.6 g of ethylene bromohydrin was added. 60-7 including mezuyu
The reaction was carried out for 1 hour at 0.

反応終了後、減圧下に溶媒を蟹去し、残澄に水を加えエ
ーテルで抽出して水洗、乾燥後エーテルを蟹去し後澄を
シリカゲルを充填したカラムに吸着させクロロホルムに
て展開した。第一流出部の溶媒を蟹去して無色プリズム
晶の2−(2ーフルオロー4−ピフェニル)ブロピオン
酸−2−ハイドロキシェチルェステル2.54夕を得た
。この物質の融点及び元素分析値は次の通りであつた。
After the reaction was completed, the solvent was removed under reduced pressure, water was added to the residue, extracted with ether, washed with water, dried, the ether was removed, and the resulting clear liquid was adsorbed onto a column packed with silica gel and developed with chloroform. The solvent in the first outflow portion was removed to obtain colorless prismatic crystals of 2-(2-fluoro-4-piphenyl)propionic acid-2-hydroxyethyl ester (2.54 g). The melting point and elemental analysis values of this substance were as follows.

融点 73〜7が○ 元素分析値 C,?日,7F03 理論値 C:70.82H:5.94 実測値 C:70.75H:5.灘 実施例 8〜20Melting point 73-7 is ○ Elemental analysis value C,? Sun, 7F03 Theoretical value C: 70.82H: 5.94 Actual value C: 70.75H: 5. Nada Examples 8-20

Claims (1)

【特許請求の範囲】 1 一般式 ▲数式、化学式、表等があります▼ (式中、nは1または2の整数を、R^1は水素原子ま
たは低級アルキル基を、R^2は(イ)水酸基、(ロ)
トリハロメチル基、(ハ)ピリジル基、(ニ)フエニル
基または(ホ)ハロゲン原子、低級アルキル基またはト
リフルオロメチル基で置換されたフエニル基を意味する
)で表わされる2−(2−フルオロ−4−ビフエニル)
プロピオン酸エステル誘導体。
[Claims] 1 General formula▲ Numerical formula, chemical formula, table, etc.▼ (In the formula, n is an integer of 1 or 2, R^1 is a hydrogen atom or a lower alkyl group, R^2 is (i) ) hydroxyl group, (b)
2-(2-fluoro- 4-biphenyl)
Propionate ester derivative.
JP7570677A 1977-06-24 1977-06-24 Novel 2-(2-fluoro-4-biphenyl)propionic acid ester derivative Expired JPS6022694B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP7570677A JPS6022694B2 (en) 1977-06-24 1977-06-24 Novel 2-(2-fluoro-4-biphenyl)propionic acid ester derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7570677A JPS6022694B2 (en) 1977-06-24 1977-06-24 Novel 2-(2-fluoro-4-biphenyl)propionic acid ester derivative

Publications (2)

Publication Number Publication Date
JPS5412356A JPS5412356A (en) 1979-01-30
JPS6022694B2 true JPS6022694B2 (en) 1985-06-03

Family

ID=13583922

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7570677A Expired JPS6022694B2 (en) 1977-06-24 1977-06-24 Novel 2-(2-fluoro-4-biphenyl)propionic acid ester derivative

Country Status (1)

Country Link
JP (1) JPS6022694B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6259289U (en) * 1985-10-02 1987-04-13

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6259289U (en) * 1985-10-02 1987-04-13

Also Published As

Publication number Publication date
JPS5412356A (en) 1979-01-30

Similar Documents

Publication Publication Date Title
JP3058863B2 (en) Manufacturing method of sildenafil
DE2432410C2 (en) 2- [4- (Imidazo [1,2a] [pyridin-2-yl) phenyl] propionic acids, process for their preparation and their use
EP0249950B1 (en) Aromatic compounds
JPH03151378A (en) Benzocycloalkylaminopyridine amines and related compounds
JPH0699396B2 (en) Novel oxazolopyridine derivative
JPS6022694B2 (en) Novel 2-(2-fluoro-4-biphenyl)propionic acid ester derivative
DE3132915A1 (en) 1,5-DIPHENYLPYRAZOLIN-3-ON-COMPOUNDS, METHODS AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
JPS62277392A (en) Sulfenamide derivative and production thereof
JPS584699B2 (en) Substituted phenylacetic acid derivatives and their production method
JPS604809B2 (en) Novel 2-(m-benzoyl)phenylpropionate derivative
US3822278A (en) N-cyclopropyl-pyridyl carboxamide derivatives
JPS6353984B2 (en)
CN111116576A (en) A kind of quinazinone compound and preparation method thereof
JPS6055510B2 (en) Method for producing 4-(p-fluorobenzoyl)-1-[3-(p-fluorobenzoyl)propyl]piperidine and its acid addition salt
DK156651B (en) METHOD OF ANALOGY FOR PREPARING PYRIDOXIN DERIVATIVES
JPS6039064B2 (en) Novel phenyl acetate derivative
US3983126A (en) Aryloxy pyridine carboxylic-4-acids
JPS6051465B2 (en) 3-Methyl-3-[4-(1-oxo-2-isoindolinyl)phenyl]pyruvic acid esters
JPS6041059B2 (en) Novel phenylpropionate derivative
JPS6125014B2 (en)
JPH0378384B2 (en)
AT343648B (en) PROCESS FOR THE PRODUCTION OF NEW SUBSTITUTED, WHERE APPROPRIATE OR AMIDATED BENZOCYCLOALKENYLCARBONIC ACIDS
JPS58134077A (en) Novel indoleacetic ester derivative and preparation thereof
CA2301074A1 (en) Crystalline 10,10-bis((2-fluoro-4-pyridinyl)methyl)-9(10h)-anthracenone and an improved process for preparing the same
CN104961674A (en) Preparation method of reference substance for synthesizing etoricoxib